Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)

Philippe Moreau,Cyrille Hulin,Denis Caillot,Gerald Marit,Aurore Perrot,Laurent Garderet,Thierry Facon,Lofti Benboubker,Lionel Karlin,Mourad Tiab,Bertrand Arnulf,Xavier Leleu,Cyrille Touzeau,Murielle Roussel,Lucie Planche,Hervé Avet-Loiseau,Thomas Dejoie,Michel Attal

doi:10.1182/blood.v130.suppl_1.2021.2021

Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)

Philippe Moreau, Cyrille Hulin + Show 16 more

https://doi.org/10.1182/blood.v130.suppl_1.2021.2021

Copy DOI

Journal: Blood	Publication Date: Jun 25, 2021
Citations: 1

Affiliation: Maison des Sciences de l’Homme de Dijon, Centre Hospitalier Universitaire de Nancy, Hôpital Saint-Antoine, Université de Tours, Hôpital Lyon Sud, Roche (France), Hôpital Saint-Louis, Centre Hospitalier Universitaire de Nantes, University Cancer Institute Toulouse Oncopole

#After Autologous Stem Cell Transplantation #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)

Full Text